Please login to the form below

Not currently logged in
Email:
Password:

CDF

This page shows the latest CDF news and features for those working in and with pharma, biotech and healthcare.

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness

Gilead’s managing director for the UK and Ireland Hilary Hutton-Squire told PME that she is confident of agreeing a deal, with access via the Cancer Drugs Fund (CDF) the

Latest news

More from news
Approximately 11 fully matching, plus 79 partially matching documents found.

Latest Intelligence

  • Sustainable solutions Sustainable solutions

    Set up in 2011 and only intended as a stop-gap measure, the demands on Cancer Drugs Fund (CDF) have grown over the years with it now running over the original ... Proposed reforms that would see it act as a 'managed access' fund with closer integration

  • The death of the cancer drugs fund? The death of the cancer drugs fund?

    According to the former health minister Paul Burstow, the CDF has been a 'missed opportunity' for all stakeholders. ... Burstow also asked whether the CDF should be just for cancer - or, in fact, just for drugs.

  • Communicating value Communicating value

    In the UK the English NHS has taken 25 cancer treatments off its formularies in the Cancer Drugs Fund (CDF), denying them to future patients only months before a general election. ... Contrast this with the 2010 election when the CDF was created as a vote

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics